Mind Medicine (MindMed) (NASDAQ:MNMD - Get Free Report)'s stock had its "overweight" rating reissued by investment analysts at Cantor Fitzgerald in a research report issued to clients and investors on Friday, Benzinga reports.
Several other equities research analysts also recently issued reports on MNMD. Oppenheimer reaffirmed an "outperform" rating and issued a $20.00 price target (down from $29.00) on shares of Mind Medicine (MindMed) in a research report on Monday, May 13th. Baird R W upgraded shares of Mind Medicine (MindMed) to a "strong-buy" rating in a research note on Wednesday, May 29th. Royal Bank of Canada reiterated an "outperform" rating and issued a $22.00 target price on shares of Mind Medicine (MindMed) in a research note on Wednesday, June 5th. Robert W. Baird started coverage on shares of Mind Medicine (MindMed) in a research note on Tuesday, May 28th. They issued an "outperform" rating and a $27.00 target price for the company. Finally, Leerink Partnrs reiterated an "outperform" rating on shares of Mind Medicine (MindMed) in a research note on Monday, April 15th. Eight analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to MarketBeat, Mind Medicine (MindMed) has an average rating of "Buy" and a consensus price target of $20.00.
Get Our Latest Research Report on Mind Medicine (MindMed)
Mind Medicine (MindMed) Stock Performance
Shares of NASDAQ:MNMD traded up $0.11 during midday trading on Friday, hitting $7.36. The company's stock had a trading volume of 4,099,914 shares, compared to its average volume of 1,732,332. The stock has a market capitalization of $517.19 million, a price-to-earnings ratio of -2.44 and a beta of 2.64. The stock's 50 day simple moving average is $8.56 and its 200 day simple moving average is $6.68. Mind Medicine has a fifty-two week low of $2.41 and a fifty-two week high of $12.22. The company has a debt-to-equity ratio of 0.07, a quick ratio of 3.91 and a current ratio of 3.91.
Mind Medicine (MindMed) (NASDAQ:MNMD - Get Free Report) last issued its quarterly earnings results on Wednesday, May 8th. The company reported ($0.60) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.66) by $0.06. As a group, research analysts anticipate that Mind Medicine will post -1.36 earnings per share for the current year.
Insiders Place Their Bets
In other news, CEO Robert Barrow sold 16,519 shares of Mind Medicine (MindMed) stock in a transaction that occurred on Monday, March 25th. The shares were sold at an average price of $9.50, for a total value of $156,930.50. Following the completion of the transaction, the chief executive officer now owns 580,202 shares in the company, valued at $5,511,919. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In other news, insider Dan Karlin sold 6,578 shares of Mind Medicine (MindMed) stock in a transaction that occurred on Monday, March 25th. The shares were sold at an average price of $9.50, for a total value of $62,491.00. Following the completion of the transaction, the insider now owns 358,452 shares in the company, valued at $3,405,294. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Robert Barrow sold 16,519 shares of Mind Medicine (MindMed) stock in a transaction that occurred on Monday, March 25th. The shares were sold at an average price of $9.50, for a total transaction of $156,930.50. Following the completion of the transaction, the chief executive officer now owns 580,202 shares of the company's stock, valued at approximately $5,511,919. The disclosure for this sale can be found here. Corporate insiders own 2.26% of the company's stock.
Institutional Inflows and Outflows
Institutional investors have recently modified their holdings of the company. Blackstone Inc. acquired a new stake in shares of Mind Medicine (MindMed) in the first quarter valued at approximately $11,749,000. Janus Henderson Group PLC acquired a new stake in shares of Mind Medicine (MindMed) in the first quarter valued at approximately $8,964,000. AWM Investment Company Inc. acquired a new stake in shares of Mind Medicine (MindMed) in the first quarter valued at approximately $7,830,000. Tidal Investments LLC acquired a new stake in shares of Mind Medicine (MindMed) in the first quarter valued at approximately $1,698,000. Finally, Moloney Securities Asset Management LLC increased its holdings in shares of Mind Medicine (MindMed) by 133.0% in the first quarter. Moloney Securities Asset Management LLC now owns 161,961 shares of the company's stock valued at $1,522,000 after purchasing an additional 92,450 shares in the last quarter. Institutional investors own 27.91% of the company's stock.
About Mind Medicine (MindMed)
(
Get Free Report)
Mind Medicine (MindMed) Inc, a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company's lead product candidates include MM-120, which is in phase 2 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and MM-402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase I clinical trials for the treatment of core symptoms of autism spectrum disorder.
Featured Stories
![Analyst Recommendations for Mind Medicine (MindMed) (NASDAQ:MNMD)](https://www.marketbeat.com/scripts/RatingsChart.ashx?Prefix=NASDAQ&Symbol=MNMD)
Before you consider Mind Medicine (MindMed), you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Mind Medicine (MindMed) wasn't on the list.
While Mind Medicine (MindMed) currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.